First-in-Human(FIH)Trialat36Months: PhaseI/IITrialat3Months: 37% and 36% reduction in mean IOP with 98% and 96% of patients off topical IOP-lowering drops in 78 mcg and 39 mcg dose groups, ...
ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase ...
SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
A privately held ophthalmic company headquartered in Southern California (Aliso Viejo). The company’s development work is ...
Irvine-based ophthalmic company SpyGlass filed for an initial public offering with the Securities and Exchange Commission earlier this month.
All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA) Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering ...
37% and 36% reduction in mean IOP with 98% and 96% of patients off topical IOP-lowering drops in 78 mcg and 39 mcg dose groups, respectively 100% of patients achieved 20/40 or better BCDVA and a mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results